1. Managing Adverse Events With New Oral Therapies in CLL

3. Expanded Treatment Options for Patients With CLL

4. Program Overview

5. Initial Case Presentation

6. Patient Selection and TEAE Management in Patients with CLL on PI3K Inhibitors

7. Case Presentation: Disease Relapse

8. Efficacy of Idelalisib + Rituximab in R/R CLL

9. Idelalisib TEAEs: Considerations for Patient Selection

10. Idelalisib-Associated Colitis

11. Idelalisib-Associated Transaminitis

12. Risk for Infection With Idelalisib Treatment

13. Immune-Mediated AEs With Idelalisib Treatment

14. Idelalisib + BR in R/R CLL: Efficacy

15. Idelalisib + BR in R/R CLL: SAEs

16. Patient Selection and TEAE Management in Patients With CLL on Btk Inhibitors

17. Case Continued: Treatment With Ibrutinib

18. Ibrutinib TEAEs: Considerations for Patient Selection

19. Efficacy of Ibrutinib in Del(17p) CLL

20. Case Continued: Ibrutinib TEAEs

21. Ibrutinib AE Profile

22. AF in Patients Treated With Ibrutinib

23. Ibrutinib-Associated Rash

24. Lymphocytosis in Patients Treated With Ibrutinib

25. Considerations in Discontinuing Ibrutinib for Toxicity

26. Patient Selection and TEAE Management in Patients With CLL on Bcl2 Inhibitors

27. Case Continued: Post Ibrutinib Relapse

28. TLS With Venetoclax

29. Reducing the Risk for TLS

30. Case Continued: Treatment With Venetoclax

31. Efficacy of Venetoclax in High-Risk CLL

32. TEAEs in Patients on Venetoclax Monotherapy

33. Managing Grade ≥ 3 Neutropenia in Patients Treated With Venetoclax

34. Practical Issues in Managing Patients on Venetoclax

35. Concluding Remarks

36. Case Discussion: Summary

37. Managing Patients With CLL: Looking Ahead

38. Abbreviations

39. Abbreviations (cont)

40. Abbreviations (cont)